Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)-Reference-Cited by-同舟云学术

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

Published:2019-04-15 Issue:7 Volume:21 Page:1625-1633
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Pratley Richard E.¹^ORCID,Emerson Scott S.²,Franek Edward³,Gilbert Matthew P.⁴,Marso Steven P.⁵,McGuire Darren K.⁶,Pieber Thomas R.⁷^ORCID,Zinman Bernard⁸^ORCID,Hansen Charlotte T.⁹,Hansen Melissa V.⁹,Mark Thomas⁹,Moses Alan C.⁹,Buse John B.¹⁰,

Affiliation:

1. AdventHealth Translational Research Institute for Metabolism and Diabetes Orlando Florida

2. University of Washington Seattle Washington

3. Mossakowski Clinical Research Centre, Polish Academy of Sciences Warsaw Poland

4. Larner College of Medicine at The University of Vermont Burlington Vermont

5. HCA Midwest Health Heart and Vascular Institute Kansas City Missouri

6. University of Texas Southwestern Medical Center Dallas Texas

7. Medical University of Graz Graz Austria

8. Lunenfeld‐Tanenbaum Research Institute, Mount Sinai HospitalUniversity of Toronto Toronto Ontario Canada

9. Novo Nordisk A/S Søborg Denmark

10. University of North Carolina School of Medicine Chapel Hill North Carolina

Funder